Search Cancer Clinical Trials

Clinical Trials

Title	Study of PX-866 and Docetaxel in Solid Tumors
Disease/Condition	Head and Neck Cancer
Description	Phase 1: The purpose is to determine the maximally tolerated dose (MTD) or recommended dose (RD) and any potential efficacy of PX-866 in combination with docetaxel in patients with solid tumors. Phase 2: The purpose is to determine the antitumor activity and safety of PX-866 in combination with docetaxel versus docetaxel alone in patients with NSCLC or SCCHN.
Eligibility Criteria	To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patient must be 18 Years and older * Patient has either locally advanced, recurrent, or metastatic NSCLC for which they have received at least 1 and no more than 2 prior systemic treatment regimens that may include up to 1 platinum based chemotherapy regimen and/or an epidermal growth factor receptor (EGFR) inhibitor OR locally advanced, recurrent or metastatic SCCHN for which they have received at least one and no more than two prior systemic treatment regimens. * The patient, in the opinion of the clinical investigator, has a life expectancy of more than 3 months.
Principal Investigator	Missak Haigentz, MD
Contact Name	Yoko Eng, NP
Phone	(718) 920-2090
Contact Email	yeng@montefiore.org
Post Date	09/15/2010
Protocol Number	11-06-238/West
Status	Recruiting
Current Trial Type	Interventional